Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel early add-on treatment for focal seizures
ChiCTR2000039510Phase 4Recruiting
- Sponsor
- Xuanwu Hospital
- Start
- Mar 2020
- Modality
- Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of perampanel in epilepsy and Focal onset seizure, sponsored by Xuanwu Hospital. Primary endpoint: 50% treatment response rate of all seizures in the maintenance phase. Started Mar 2020; status: recruiting.
02
Drugs
perampanel
03
Conditions
epilepsyFocal onset seizure
Beyond the preview
Go deeper on ChiCTR2000039510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039510.